NEW YORK, Aug. 6 – Venture capital firm Morgenthaler has closed $850 million in a new fund that it will use to double its early-stage investments in the health-care sector, the company said on Monday.

Morgenthaler, with offices in Cleveland and Menlo Park, Calif., has in the past invested in genomics companies including Protogene, which develops DNA microarrays, and Sequana Therapeutics, now a subsidiary of Celera Genomics as a part of Axys Pharmaceuticals.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.